BILL ANALYSIS

HR6897

NEUTRAL

Thyroid Disease CARE Act of 2025

HR6897 (Thyroid Disease CARE Act of 2025) has been assessed with a neutral outlook for investors. This legislation directly affects $DGX, $LH and Thermo Fisher Scientific ($TMO). The primary sectors impacted are Healthcare and Technology. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR6897 authorizes $30M/year for five years for thyroid research — but no funds are allocated, and the bill is stuck in committee with no action since introduction

The bill has only one cosponsor and a Democratic lead in a Republican House — passage probability is low in the 119th Congress

Even if fully funded, the $150M total is immaterial to major diagnostics companies (Q1 2026 revenue for $DGX alone exceeds $2.3 billion)

Market data shows diagnostic stocks trending negative; any bill-driven catalyst is speculative at this stage

How HR6897 Affects the Market

HR6897 is a procedural bill with no near-term market impact. Real market data shows diagnostic stocks $DGX, $LH, and all declining over the past 30 days (down 0.41%, 1.53%, and 11.85% respectively), driven by broader healthcare sector pressures, not legislative events. Thermo Fisher ($TMO) is also down 3.42% in the same period. The $30M annual authorization is too small to move pricing on these stocks even if appropriated. Investors should not trade diagnostic tickers based on this bill. The only potential catalyst would be the bill advancing to a committee markup or receiving a Senate companion — neither of which has occurred.

Bill Details

Metric	Value
Bill Number	HR6897
Market Sentiment	neutral
Event Date	December 18, 2025
Affected Sectors	Healthcare, Technology
Affected Stocks	$DGX, $LH, Thermo Fisher Scientific ($TMO)
Source	View on Congress.gov →

Summary

HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.

Full AI Market Analysis

1) What happened: Representative Stevens (D-MI) introduced HR6897, the Thyroid Disease CARE Act of 2025, on December 18, 2025. The bill was referred to the House Committee on Energy and Commerce, where it remains with no further action. With only one cosponsor (Rep. Underwood, D-IL), the bill has narrow bipartisan support, and the current House majority (Republicans) has not advanced it. 2) The money trail: Section 2(c) authorizes $30 million per fiscal year for 2026 through 2030 — a total of $150 million. This is an AUTHORIZATION, not an appropriation. The actual spending requires a separate appropriations bill passed by both chambers. Given the current fiscal environment and the bill's early stage, no funds are currently allocated. 3) Structural winners and losers: Companies in thyroid diagnostics and research tools ($DGX, $LH, $TMO, , ) would be the most directly exposed if the bill progresses and appropriations are made. However, $150 million over five years is modest — roughly equivalent to 0.1-0.3% of annual revenue for these companies. No company receives a direct earmark. 4) Market data context: As of April 30, 2026, thyroid diagnostic companies show weakness. trades at $90.50, near its 52-week low of $90.29, with a 30-day decline of 11.85%. $LH is down 1.53% over 30 days to $262.73. $DGX is essentially flat over 30 days (-0.41%) at $195.17. Research tool provider $TMO has fallen 3.42% in 30 days to $474.70. These moves are unrelated to a bill that has been dormant for over four months. 5) Timeline: The bill requires committee markup in Energy and Commerce, House floor passage, Senate companion introduction and passage, then presidential signature. With a single cosponsor and a Democratic lead sponsor in a Republican-controlled House, the probability of passage in the 119th Congress is low. No hearings or markups have been scheduled as of April 30, 2026.